Press release
Investigation announced for Long-Term Investors in shares of Tempus AI, Inc. (NASDAQ: TEM) over potential Wrongdoing
An investigation on behalf of current long term investors in Tempus AI, Inc. (NASDAQ: TEM) shares.
Investors who are current long term investors in Tempus AI, Inc. (NASDAQ: TEM) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: TEM stocks follows a lawsuit filed against Tempus AI, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: TEM stocks, concerns whether certain Tempus AI, Inc. officers and directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 6, 2024 and May 27, 2025, Tempus AI, Inc. branded itself as an AI company despite having little history of generating significant revenues from AI solutions; instead, the Company generated most of its revenues from acquisitions, genomic testing and data licensing agreements, that the Defendants repeatedly claimed that the contract value and quality of its data licensing agreements with life science companies were secure and expanding, that Tempus AI, Inc. often reported on its relationship with long-term customer AstraZeneca as an example, that importantly between August 6, 2024 and May 27, 2025, Tempus AI, Inc. announced an expanding contract with AstraZeneca via a joint venture between the Company, AstraZeneca and Pathos AI, that the Company similarly announced a joint venture with SoftBank as a way to generate revenue growth by entering the Japanese market, that Tempus AI, Inc. additionally claimed high revenue potential for Ambry Genetics ("Ambry"), a target it acquired between August 6, 2024 and May 27, 2025, and that Tempus AI, Inc. claimed that Ambry's accelerated growth was on account of its strong relationships with health care providers.
Those who purchased shares of Tempus AI, Inc. (NASDAQ: TEM) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Tempus AI, Inc. (NASDAQ: TEM) over potential Wrongdoing here
News-ID: 4168937 • Views: …
More Releases from Shareholders Foundation, Inc.
Biohaven Ltd. (NYSE: BHVN) Long Term Investor Alert: Investigation of potential …
An investigation on behalf of current long-term investors in shares of Biohaven Ltd. (NYSE: BHVN) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Biohaven Ltd. (NYSE: BHVN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE:…
Lawsuit filed for Investors who lost money with shares of V.F. Corporation (NYSE …
An investor, who purchased shares of V.F. Corporation (NYSE: VFC), filed a lawsuit over alleged violations of Federal Securities Laws by V.F. Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of V.F. Corporation (NYSE: VFC) have certain options and for certain investors are short and strict deadlines running. Deadline: November 12, 2025. NYSE: VFC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Investigation announced for Long-Term Investors in shares of Fiserv, Inc. (NYSE: …
An investigation was announced for current long-term investors in shares of Fiserv, Inc. (NYSE: FI) concerning potential breaches of fiduciary duties by certain directors of Fiserv, Inc..
Investors who are current long term investors in Fiserv, Inc. (NYSE: FI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: FI…
Novo Nordisk A/S (NYSE: NVO) Investor Alert: Deadline in Lawsuit on September 30 …
A deadline is coming up on September 30, 2025 in the lawsuit filed for certain investors of Novo Nordisk A/S (NYSE: NVO) over alleged securities laws violations by Novo Nordisk A/S.
Investors who purchased shares of Novo Nordisk A/S (NYSE: NVO) have certain options and there are strict and short deadlines running. Deadline: September 30, 2025. Novo Nordisk A/S (NYSE: NVO) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
More Releases for Tempus
Tempus AI, Inc. (NASDAQ: TEM) Shareholder Notice: Deadline in Lawsuit on August …
The Shareholders Foundation announced that a deadline is coming up on August 12, 2025 in the lawsuit filed for certain investors of Tempus AI, Inc. (NASDAQ: TEM) over alleged securities laws violations by Tempus AI, Inc.
Investors who purchased shares of Tempus AI, Inc. (NASDAQ: TEM) have certain options and there are strict and short deadlines running. Deadline: August 12, 2025. NASDAQ: TEM stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Genomics In Cancer Care Market is Booming Worldwide |Invitae,Helix, Tempus
HTF MI just released the Global Genomics In Cancer Care Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major Manufacturers are covered: Foundation Medicine (United States), Guardant…
Predictive Disease Analytics Market Is Booming So Rapidly | Tempus, Verily, Pala …
The Global Predictive Disease Analytics Market Size is estimated at $3.5 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 21.4% to reach $20 Billion by 2034.
The latest study released on the Global Predictive Disease Analytics Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Predictive Disease Analytics market study covers significant research data and proofs to be a handy…
AI in Medical Diagnostics Market Is Booming So Rapidly | Aidoc, Tempus, Lunit
USD Analytics recently introduced Global AI in Medical Diagnostics Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are IBM Watson Health, GE Healthcare, Siemens Healthineers, Zebra…
AI in Oncology Market SWOT Analysis by Leading Expert: Tempus, Oncora, PerkinElm …
USD Analytics recently introduced Global AI in Oncology Market study with 143+ pages in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status (2024-2032). The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are IBM Watson Health, Tempus, GE Healthcare, Siemens Healthineers, Varian…
Artificial Intelligence In Precision Medicine Market Is Booming So Rapidly: IBM, …
The latest study released on the Global Artificial Intelligence In Precision Medicine Market by USD Analytics Market evaluates market size, trend, and forecast to 2032. The Artificial Intelligence In Precision Medicine market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming…
